| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/200 - 1/1000 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | FH; FHC; LDLCQ2 |
| Entrez GeneID | 3949 |
| clone | 1B10H10 |
| WB Predicted band size | 95.4kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Purified recombinant fragment of human LDLR (AA: 22-150) expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于LDLR抗体的3篇代表性文献及其摘要：
---
1. **标题**: "Monoclonal Antibodies to the Low Density Lipoprotein Receptor as Probes for Study of Receptor-mediated Endocytosis"
**作者**: Beisiegel, U., Schneider, W.J., Goldstein, J.L., Brown, M.S.
**摘要**: 该研究通过制备针对LDLR的单克隆抗体，揭示了抗体与受体结合后阻断LDL内吞的作用机制，证实了LDLR在胆固醇摄取中的关键功能，并为受体介导的内吞途径提供了分子证据。
2. **标题**: "Structural Localization of Epitopes on the LDL Receptor Identified by Monoclonal Antibodies"
**作者**: Russell, D.W., Yamamoto, T., Schneider, W.J. et al.
**摘要**: 作者利用单克隆抗体定位LDLR的表位结构域，发现不同抗体分别结合受体的配体结合区、EGF前体同源区等区域，为解析LDLR的构效关系及遗传突变导致的疾病(如家族性高胆固醇血症)提供了结构基础。
3. **标题**: "Antibody-Mediated Disruption of the Interaction Between PCSK9 and LDLR Enhances LDL Uptake"
**作者**: Zhang, L., McCabe, T., Condra, J.H. et al.
**摘要**: 研究开发了一种靶向PCSK9的单克隆抗体，通过阻断PCSK9与LDLR的结合，减少LDLR的溶酶体降解，从而增加细胞表面LDLR密度，促进血浆LDL-C清除，为治疗高胆固醇血症提供了新策略。
---
这些文献涵盖了LDLR抗体的功能研究、结构解析及治疗应用，反映了该领域的关键研究方向。如需具体细节，建议通过学术数据库检索原文。
Low-density lipoprotein receptor (LDLR) antibodies are tools used to study the LDLR, a cell-surface protein critical for regulating cholesterol homeostasis. LDLR mediates the uptake of LDL cholesterol particles via receptor-mediated endocytosis, a process essential for maintaining plasma cholesterol levels. Dysfunctional LDLR, often due to genetic mutations, is linked to familial hypercholesterolemia (FH), a condition characterized by elevated LDL cholesterol and increased cardiovascular risk.
LDLR antibodies, including monoclonal and polyclonal types, are widely employed in research to detect LDLR expression, track its intracellular trafficking, or modulate its activity. For example, some antibodies act as antagonists to block LDL binding, mimicking therapeutic strategies like PCSK9 inhibitors, which enhance LDLR recycling and lower cholesterol. Conversely, agonist antibodies may stabilize LDLR to boost LDL clearance. These applications make LDLR antibodies valuable in studying atherosclerosis, metabolic disorders, and lipid metabolism pathways.
Additionally, LDLR antibodies have diagnostic potential, aiding in identifying FH patients with receptor defects. Emerging therapeutic approaches also explore antibody-based targeting of LDLR to treat hypercholesterolemia or cancers where LDLR is overexpressed. However, challenges remain in ensuring specificity and minimizing off-target effects. Overall, LDLR antibodies serve as pivotal reagents in both basic research and translational studies of cholesterol-related diseases.
×
